P63 Effectiveness of biologics in clinical practice: Month 12 absolute psoriasis area and severity index outcomes from an international observational Psoriasis Study of Health Outcomes

Abstract Introduction Absolute psoriasis area and severity index (PASI) may be an alternative to relative PASI for treatment comparisons because it reflects both clinically meaningful improvements in disease activity and informs treatment decisions based on actual disease severity, regardless of baseline score. The Psoriasis Study of Health Outcomes (PSoHO) is a 3-year, international, prospective, non-interventional study comparing the effectiveness of anti-IL-17A biologics [ixekizumab (IXE) and secukinumab (SEC)] to other approved biologics in patients with moderate-to-severe psoriasis (PsO) undergoing routine medical care. While relative PASI effectiveness has been reported at 12 months, absolute PASI responses have not yet been shown. This analysis aims to report the effectiveness measured by absolute PASI through 12 months. Methods PSoHO included patients with moderate-to-severe plaque PsO, initiating or switching to a new approved biologic treatment (including biosimilars). This analysis reports the percentage of patients receiving EMA-approved on-label dosing (n = 1678), who achieved absolute PASI scores ≤1, ≤2 and ≤3 at Months 6 and 12. Unadjusted response rates for absolute PASI scores are reported as percentages for each outcome and time point. Non-responder imputation (NRI) was used for missing outcomes and reported here. Results At Month 6, higher response rates for absolute PASI ≤1, ≤2 and ≤3 were achieved by 62.2, 72.1 and 77.8% of patients in the anti-IL-17A cohort compared with 47.4, 61.3 and 69.7% of patients in the other biologics cohort respectively. At Month 12, higher response rates for absolute PASI ≤1, ≤2 and ≤3 were achieved by 56.5, 66.2 and 71.2% of patients in the anti-IL-17A cohort compared with 50.3, 62.6 and 69.0% in the other biologics cohort respectively. At Month 6, across individual treatments, IXE provided the highest response rates in absolute PASI ≤1, ≤2 and ≤3 with 65.2, 74.0 and 79.2%, respectively. At Month 12, IXE showed the highest response rates in absolute PASI ≤1 with 59.6%, followed by risankizumab, guselkumab, tildrakizumab, secukinumab, brodalumab, adalimumab, and ustekinumab with 57.5, 51.5, 51.2, 50.0, 46.7, 44.8, and 42.4% respectively. Conclusion This analysis indicates that the anti-IL-17A cohort of the EMA-approved on-label population had a higher response rate in absolute PASI through Month 12, in a real-world setting. Across individual drug treatments, IXE indicated the highest percentage of patients achieving key endpoints at both 6 and 12 months.